• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种IgG2单克隆抗体两种不同二聚体的结构变化与聚集机制

Structural Changes and Aggregation Mechanisms of Two Different Dimers of an IgG2 Monoclonal Antibody.

作者信息

Zhang Jun, Woods Christopher, He Feng, Han Mei, Treuheit Michael J, Volkin David B

机构信息

Process Development , Amgen Inc. , Thousand Oaks , California 91320 , United States.

Department of Pharmaceutical Chemistry, Macromolecule and Vaccine Stabilization Center , University of Kansas , Lawrence , Kansas 66049 , United States.

出版信息

Biochemistry. 2018 Sep 18;57(37):5466-5479. doi: 10.1021/acs.biochem.8b00575. Epub 2018 Sep 5.

DOI:10.1021/acs.biochem.8b00575
PMID:30141909
Abstract

Protein therapeutics, monoclonal antibodies (mAbs) in particular, are large, structurally complex molecules that are prone to numerous modes of degradation during their production and long-term storage. Physical degradation via protein aggregation is a major concern when developing protein therapeutic candidates for clinical use. A dimer is perhaps the simplest element of protein aggregation, and thus, a better understanding of protein dimers in terms of their structures, intermolecular interactions, and chemical nature will help in the development of rational strategies for reducing aggregation propensity. In this study, two different mAb dimers were generated from an IgG2 monoclonal antibody solution, i.e., a native dimer generated under long-term storage and a thermal dimer from a thermal stress condition. Both IgG2 dimers were characterized in terms of their chemical and physical properties, bioactivity, and conformational dynamics. The native IgG2 dimer was formed mainly through noncovalent association. It displayed minimal differences in biophysical properties and higher-order structure compared to the monomer yet showed compromised in vitro potency, likely because of steric hindrance. In contrast, the thermal IgG2 dimer was mainly disulfide-linked, but even so, no new non-native disulfide bonds were detected by peptide mapping. Two regions within the Fc-C2 domain of the thermal IgG2 dimer exhibited significantly increased flexibility as measured by hydrogen-deuterium exchange mass spectrometry, and notably, these regions are connected by an intrachain disulfide bond under natively folded conditions. These findings provide a better understanding of dimer formation under long-term storage and thermal stress conditions for this IgG2 mAb, and possible aggregation mechanisms are discussed.

摘要

蛋白质疗法,尤其是单克隆抗体(mAbs),是大型的、结构复杂的分子,在其生产和长期储存过程中容易出现多种降解方式。在开发用于临床的蛋白质治疗候选药物时,通过蛋白质聚集进行的物理降解是一个主要问题。二聚体可能是蛋白质聚集中最简单的元素,因此,从其结构、分子间相互作用和化学性质方面更好地理解蛋白质二聚体,将有助于制定合理的策略来降低聚集倾向。在本研究中,从一种IgG2单克隆抗体溶液中产生了两种不同的mAb二聚体,即长期储存条件下产生的天然二聚体和热应激条件下产生的热二聚体。对这两种IgG2二聚体的化学和物理性质、生物活性以及构象动力学进行了表征。天然IgG2二聚体主要通过非共价缔合形成。与单体相比,它在生物物理性质和高级结构上显示出最小的差异,但体外效力受损,可能是由于空间位阻。相比之下,热IgG2二聚体主要是通过二硫键连接,但即便如此,通过肽图分析未检测到新的非天然二硫键。通过氢-氘交换质谱法测定,热IgG2二聚体的Fc-C2结构域内的两个区域表现出显著增加的灵活性,值得注意的是,在天然折叠条件下,这些区域通过链内二硫键相连。这些发现有助于更好地理解这种IgG2 mAb在长期储存和热应激条件下的二聚体形成,并讨论了可能的聚集机制。

相似文献

1
Structural Changes and Aggregation Mechanisms of Two Different Dimers of an IgG2 Monoclonal Antibody.一种IgG2单克隆抗体两种不同二聚体的结构变化与聚集机制
Biochemistry. 2018 Sep 18;57(37):5466-5479. doi: 10.1021/acs.biochem.8b00575. Epub 2018 Sep 5.
2
The impact of forced degradation conditions on mAb dimer formation and subsequent influence on aggregation propensity.强制降解条件对 mAb 二聚体形成的影响及其对聚集倾向的后续影响。
MAbs. 2022 Jan-Dec;14(1):2127172. doi: 10.1080/19420862.2022.2127172.
3
Understanding the Increased Aggregation Propensity of a Light-Exposed IgG1 Monoclonal Antibody Using Hydrogen Exchange Mass Spectrometry, Biophysical Characterization, and Structural Analysis.使用氢交换质谱、物理化学特性分析和结构分析来理解光照暴露的 IgG1 单克隆抗体的聚集倾向增加。
J Pharm Sci. 2018 Jun;107(6):1498-1511. doi: 10.1016/j.xphs.2018.01.017. Epub 2018 Jan 31.
4
Conformational difference in human IgG2 disulfide isoforms revealed by hydrogen/deuterium exchange mass spectrometry.氢/氘交换质谱法揭示的人IgG2二硫键异构体的构象差异
Biochemistry. 2015 Mar 17;54(10):1956-62. doi: 10.1021/bi5015216. Epub 2015 Mar 5.
5
Investigating monoclonal antibody aggregation using a combination of H/DX-MS and other biophysical measurements.采用 H/DX-MS 与其他生物物理测量相结合的方法研究单克隆抗体聚集。
J Pharm Sci. 2013 Dec;102(12):4315-29. doi: 10.1002/jps.23754. Epub 2013 Oct 17.
6
Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life.为延长血清半衰期而改造的突变型IgG1单克隆抗体的构象动力学变化与物理稳定性之间的相关性。
MAbs. 2015;7(1):84-95. doi: 10.4161/19420862.2014.985494.
7
Characterization of mAb dimers reveals predominant dimer forms common in therapeutic mAbs.单克隆抗体二聚体的表征揭示了治疗性单克隆抗体中常见的主要二聚体形式。
MAbs. 2016 Jul;8(5):928-40. doi: 10.1080/19420862.2016.1168960. Epub 2016 Mar 31.
8
Distinctive Low-Resolution Structural Features of Dimers of Antibody-Drug Conjugates and Parent Antibody Determined by Small-Angle X-ray Scattering.小角 X 射线散射法测定抗体药物偶联物二聚体和母体抗体的独特低分辨率结构特征。
Mol Pharm. 2019 Dec 2;16(12):4902-4912. doi: 10.1021/acs.molpharmaceut.9b00792. Epub 2019 Oct 30.
9
Elucidation of two major aggregation pathways in an IgG2 antibody.IgG2抗体中两条主要聚集途径的阐释。
J Pharm Sci. 2009 Sep;98(9):3013-30. doi: 10.1002/jps.21514.
10
Acid-induced aggregation of human monoclonal IgG1 and IgG2: molecular mechanism and the effect of solution composition.酸诱导的人源单克隆 IgG1 和 IgG2 聚集:分子机制及溶液组成的影响。
Biochemistry. 2010 Nov 2;49(43):9328-38. doi: 10.1021/bi100841u.

引用本文的文献

1
Opportunities and Challenges in Antibody-Drug Conjugates for Cancer Therapy: A New Era for Cancer Treatment.抗体药物偶联物用于癌症治疗的机遇与挑战:癌症治疗的新时代
Cancers (Basel). 2025 Mar 12;17(6):958. doi: 10.3390/cancers17060958.
2
Antibody-drug conjugates in urothelial carcinoma: scientometric analysis and clinical trials analysis.尿路上皮癌中的抗体药物偶联物:科学计量学分析与临床试验分析
Front Oncol. 2024 Mar 14;14:1323366. doi: 10.3389/fonc.2024.1323366. eCollection 2024.
3
Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy.
癌症治疗用抗体药物偶联物的发展趋势
Antibodies (Basel). 2023 Nov 3;12(4):72. doi: 10.3390/antib12040072.
4
The Evolving Landscape of Antibody-Drug Conjugates: In Depth Analysis of Recent Research Progress.抗体药物偶联物的发展现状:对近期研究进展的深入分析。
Bioconjug Chem. 2023 Nov 15;34(11):1951-2000. doi: 10.1021/acs.bioconjchem.3c00374. Epub 2023 Oct 11.
5
A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy.抗体药物偶联物综述:从概念形成到癌症治疗
Front Pharmacol. 2023 Sep 18;14:1274088. doi: 10.3389/fphar.2023.1274088. eCollection 2023.
6
Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging.用于癌症治疗的单克隆抗体的治疗靶点:现状与新进展
Biomedicines. 2023 Jul 24;11(7):2086. doi: 10.3390/biomedicines11072086.
7
Rapid Characterization of Antibodies via Automated Flow Injection Coupled with Online Microdroplet Reactions and Native-pH Mass Spectrometry.通过自动化流注射与在线微滴反应和原生 pH 质谱联用快速鉴定抗体。
Anal Chem. 2023 Feb 14;95(6):3340-3348. doi: 10.1021/acs.analchem.2c04535. Epub 2023 Jan 19.
8
The impact of forced degradation conditions on mAb dimer formation and subsequent influence on aggregation propensity.强制降解条件对 mAb 二聚体形成的影响及其对聚集倾向的后续影响。
MAbs. 2022 Jan-Dec;14(1):2127172. doi: 10.1080/19420862.2022.2127172.
9
Antibody drug conjugate: the "biological missile" for targeted cancer therapy.抗体药物偶联物:靶向癌症治疗的“生物导弹”。
Signal Transduct Target Ther. 2022 Mar 22;7(1):93. doi: 10.1038/s41392-022-00947-7.
10
Aggregation Time Machine: A Platform for the Prediction and Optimization of Long-Term Antibody Stability Using Short-Term Kinetic Analysis.聚集时间机器:使用短期动力学分析预测和优化长期抗体稳定性的平台。
J Med Chem. 2022 Feb 10;65(3):2623-2632. doi: 10.1021/acs.jmedchem.1c02010. Epub 2022 Jan 28.